GS
The Goldman Sachs Group, Inc.
GS's fundamentals are strong: revenue grew 19% and its operating margin rose 4 points to 40%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
NMR
Nomura Holdings, Inc.
There isn't enough reported data to score NMR yet.
GS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| N/A | |
| N/A |
GS's revenue and profitability are currently strong. Free cash flow and net leverage aren't meaningful measures for financial services companies like GS.
NMR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| N/A | |
| N/A |
NMR's profitability is currently healthy. There isn't enough data to rate its revenue. Free cash flow and net leverage aren't meaningful measures for financial services companies like NMR.
GS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.6x | $528 | -42% |
| Current | 13x | $914 | — |
| Forward | 13x | $914 | — |
| Fair | 14x | $940 | +2.9% |
| Expensive | 17x | $1,214 | +33% |
Historical ranges are pointers, not guarantees.
GS's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
NMR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.9x | $5.90 | -38% |
| Fair | 12x | $8.70 | -9% |
| Current | 13x | $9.56 | — |
| Expensive | 18x | $13.82 | +45% |
Historical ranges are pointers, not guarantees.
NMR has the edge over GS in the historical PE scenario, which offers more potential upside but is not a forecast.
GS Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
GS has the edge over NMR on the outlook, with more favorable earnings and profitability expectations.
NMR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| High |
Analysts expect NMR's revenue to grow, but its profitability to weaken.
GS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $72.35 | +4% |
| Q3 2026 | $69.58 | +41% |
| Q2 2026 | $64.82 | +43% |
| Q1 2026 | $54.75 | +27% |
| Q4 2025 | $51.32 | +27% |
| Q3 2025 | $49.22 | +44% |
| Q2 2025 | $45.37 | +45% |
| Q1 2025 | $43.08 | +68% |
| Q4 2024 | $40.54 | +77% |
GS's earnings per share have climbed steadily: $69.58 over the past year, up 41% from the year before, and higher year over year for 10 quarters in a row. Its recent earnings include one-off gains.
NMR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2026 | $0.75 | +7.1% |
| Q3 2025 | $0.76 | +36% |
| Q1 2025 | $0.70 | +112% |
| Q3 2024 | $0.56 | +107% |
| Q1 2024 | $0.33 | +74% |
| Q3 2023 | $0.27 | +23% |
| Q1 2023 | $0.19 | -32% |
| Q3 2022 | $0.22 | +$0.23 |
NMR has the edge over GS in the latest year-over-year earnings comparison.
GS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $18.7B | +23% |
| Q2 2026 | $20.3B | +39% |
| Q1 2026 | $17.2B | +14% |
| Q4 2025 | $13.5B | -3% |
| Q3 2025 | $15.2B | +20% |
| Q2 2025 | $14.6B | +15% |
| Q1 2025 | $15.1B | +6% |
| Q4 2024 | $13.9B | +23% |
GS's revenue is growing: $18.7B last quarter, up 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 37% | +2 points |
| Q2 2026 | 42% | +8.1 points |
| Q1 2026 | 38% | +0.2 points |
| Q4 2025 | 44% | +5.6 points |
| Q3 2025 | 36% | +4.1 points |
| Q2 2025 | 34% | +3.2 points |
| Q1 2025 | 37% | +0.6 points |
| Q4 2024 | 38% | +18 points |
GS's operating margin was 37% last quarter, up 2 points from the same quarter a year ago.
NMR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $7.1B | +18% |
| Q3 2025 | $6.5B | +11% |
| Q1 2025 | $6B | +13% |
| Q3 2024 | $5.9B | +31% |
| Q1 2024 | $5.3B | +18% |
| Q3 2023 | $4.5B | +16% |
| Q1 2023 | $4.5B | +3.9% |
| Q3 2022 | $3.9B | -8.2% |
NMR has the edge over GS in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | 21% | -0.3 points |
| Q3 2025 | 28% | +14 points |
| Q1 2025 | 25% | +6.3 points |
| Q3 2024 | 25% | +18 points |
| Q1 2024 | 21% | +2.6 points |
| Q3 2023 | 15% | +0.9 points |
| Q1 2023 | 18% | +26 points |
| Q3 2022 | 7.8% | -24 points |
NMR's operating margin was 21% last quarter, about level with the same quarter a year ago.
GS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +72% |
| Q2 2026 | $5.6B | +7.8% |
| Q1 2026 | -$32.4B | +$5.3B |
| Q4 2025 | -$16.8B | -136% |
| Q3 2025 | $2.1B | +$40.6B |
| Q2 2025 | $5.2B | -6.8% |
| Q1 2025 | -$37.7B | -$9.2B |
| Q4 2024 | $46.2B | +$75.1B |
GS's free cash flow was −$40B over the past year, against $15.8B the year before. Free cash flow isn't a meaningful measure for financial services companies like GS.
NMR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$12.7B | -$10.1B |
| Q3 2025 | $5.2B | +$8B |
| Q1 2025 | -$2.6B | -$1.6B |
| Q3 2024 | -$2.8B | -420% |
| Q1 2024 | -$968.3M | -$27.3M |
| Q3 2023 | $885.9M | +$5.4B |
| Q1 2023 | -$941M | +$6.6B |
| Q3 2022 | -$4.5B | -$2.8B |
NMR's free cash flow was −$12.9B over the past year, against −$5.5B the year before. Free cash flow isn't a meaningful measure for financial services companies like NMR.
GS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -3.8M shares |
| 1 year | -4.4% | -13.9M shares |
| 3 years | -12% | -42.8M shares |
| 5 years | -15% | -52.8M shares |
| Available history | -20% | -74.4M shares |
GS has 301M diluted shares, down 4.4% from a year ago, with $15B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3B |
| Q2 2026 | $4B |
| Q1 2026 | $5B |
| Q4 2025 | $3B |
| Q3 2025 | $2B |
| Q2 2025 | $3B |
| Q1 2025 | $4.4B |
| Q4 2024 | $2B |
GS spent $15B buying back its own shares over the past year, up 32% from the year before.
NMR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -9.6% | -325M shares |
| 1 year | -14% | -498M shares |
| 3 years | -20% | -781M shares |
NMR has the edge over GS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2026 | $260.1M |
| Q3 2025 | $376.1M |
| Q1 2025 | $50,144 |
| Q3 2024 | $369.8M |
| Q1 2024 | $257.1M |
| Q3 2023 | $125.4M |
| Q1 2023 | $9.5M |
| Q3 2022 | $145.5M |
GS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -5.4x | Net Cash |
| Q2 2026 | -6.1x | Net Cash |
| Q1 2026 | -6.7x | Net Cash |
| Q4 2025 | -6.4x | Net Cash |
| Q3 2025 | -3.5x | Net Cash |
| Q2 2025 | -3.1x | Net Cash |
| Q1 2025 | -3.9x | Net Cash |
| Q4 2024 | -4.7x | Net Cash |
GS has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like GS.
NMR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 21.7x | High |
| Q3 2025 | 16.5x | High |
| Q1 2025 | 18.8x | High |
| Q3 2024 | 19.0x | High |
| Q1 2024 | 26.8x | High |
| Q3 2023 | 28.2x | High |
| Q1 2023 | 31.5x | High |
| Q3 2022 | 32.4x | High |
NMR's net debt is more than 20 years of its operating earnings (EBITDA), down from more than 20 years a year ago. Net leverage isn't a meaningful measure for financial services companies like NMR.
GS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.5 | Neutral |
| Stochastic | 16.3 | Oversold |
GS's weekly RSI is 45 (neutral) and its Stochastic is 16 (oversold).
NMR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.8 | Neutral |
| Stochastic | 26.2 | Neutral |
NMR's weekly RSI is 53 (neutral) and its Stochastic is 26 (neutral).
GS PE vs Financial Services Sector
| Metric | GS | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 13x | 0.8% above |
| PE % | 46 | 63 | 17 pts below |
GS is trading at 13x earnings, in line with the Financial Services sector's median of 13x, though its earnings don't support one.
NMR PE vs Financial Services Sector
| Metric | NMR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 13x | 1.5% below |
| PE % | 59 | 63 | 4 pts below |
NMR has the edge over GS on valuation relative to its sector.
GS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $895.5 | 2% above |
| 20 week MA | $977.4 | 6.5% below |
| 50 week MA | $945.4 | 3.4% below |
| 100 week MA | $804.5 | 14% above |
| 200 week MA | $602.7 | 52% above |
GS's trend is mixed: it's above three of its five weekly moving averages, and 52% above its 200-week average.
NMR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.49 | 0.7% above |
| 20 week MA | $9.75 | 1.9% below |
| 50 week MA | $8.94 | 6.9% above |
| 100 week MA | $7.73 | 24% above |
| 200 week MA | $6.28 | 52% above |
NMR has the edge over GS on trend strength, trading above more of its moving averages.
GS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $230.7 | $256.2 | +11% |
| 2021 | $256.2 | $385.0 | +50% |
| 2022 | $385.0 | $345.5 | -10% |
| 2023 | $345.5 | $385.8 | +12% |
| 2024 | $385.8 | $576.2 | +49% |
| 2025 | $576.2 | $907.0 | +57% |
| 2026 YTD | $907.0 | $913.6 | +0.7% |
GS has finished higher in five of the last six years, two of them by more than 50%. It's up 0.7% so far in 2026.
NMR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.12 | $5.22 | +2% |
| 2021 | $5.22 | $4.43 | -15% |
| 2022 | $4.43 | $3.68 | -17% |
| 2023 | $3.68 | $4.51 | +23% |
| 2024 | $4.51 | $5.86 | +30% |
| 2025 | $5.86 | $8.41 | +44% |
| 2026 YTD | $8.41 | $9.56 | +14% |
NMR has the edge over GS on returns for 2026, with the stronger performance.